Data / Drug companies / Tagi Pharma, Inc.
Tagi Pharma, Inc.: 13 products in the FDA NDC directory, labeler code 51224
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Tagi Pharma, Inc. (labeler code 51224) lists 13 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 13 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 5, 2022.
The request: Watch Tagi Pharma, Inc. (FDA labeler code 51224): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51224
- Products in commercial distribution
- 13
- Packages
- 20
- Finished drugs by generic name
- 9
- Prescription products
- 13
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 1
- Flagged as original packager
- 13 of 13 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 7
- Earliest marketing start
- April 17, 2008
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 13 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 13 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Benzonatate | 2 | 42 |
| Cholestyramine | 2 | 14 |
| Gabapentin | 2 | 91 |
| Chlorthalidone | 2 | 42 |
| Azithromycin dihydrate | 1 | 20 |
| Metformin hydrochloride | 1 | 79 |
| Levetiracetam | 1 | 87 |
| Naltrexone hydrochloride | 1 | 24 |
| Phentermine hydrochloride | 1 | 26 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 3 | 23.1% |
| Capsule | 2 | 15.4% |
| Tablet, film coated | 2 | 15.4% |
| Powder, for suspension | 2 | 15.4% |
| Tablet, coated | 2 | 15.4% |
| Tablet, extended release | 1 | 7.7% |
| Injection, solution, concentrate | 1 | 7.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Non-narcotic Antitussive | 2 |
| Bile Acid Sequestrant | 2 |
| Thiazide-like Diuretic | 2 |
| Macrolide Antimicrobial | 1 |
| Biguanide | 1 |
| Opioid Antagonist | 1 |
| Sympathomimetic Amine Anorectic | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Chlorthalidone | 51224-118 | Tablet | Generic drugs (ANDA) | August 5, 2022 |
| Chlorthalidone | 51224-018 | Tablet | Generic drugs (ANDA) | August 5, 2022 |
| Cholestyramine | 51224-011 | Powder, for suspension | Generic drugs (ANDA) | March 10, 2021 |
| Cholestyramine Light | 51224-009 | Powder, for suspension | Generic drugs (ANDA) | November 12, 2020 |
| Azithromycin Dihydrate | 51224-022 | Tablet, film coated | Generic drugs (ANDA) | July 1, 2019 |
| Gabapentin | 51224-121 | Tablet, coated | Generic drugs (ANDA) | May 1, 2019 |
| Gabapentin | 51224-021 | Tablet, coated | Generic drugs (ANDA) | May 1, 2019 |
| Levetiracetam | 51224-013 | Injection, solution, concentrate | Generic drugs (ANDA) | November 30, 2018 |
| Benzonatate | 51224-010 | Capsule | Generic drugs (ANDA) | September 7, 2017 |
| Benzonatate | 51224-001 | Capsule | Generic drugs (ANDA) | August 10, 2015 |
| Naltrexone Hydrochloride | 51224-206 | Tablet, film coated | Generic drugs (ANDA) | September 23, 2013 |
| Phentermine Hydrochloride | 51224-101 | Tablet | Generic drugs (ANDA) | March 8, 2011 |
| Metformin Hydrochloride | 51224-107 | Tablet, extended release | Generic drugs (ANDA) | April 17, 2008 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.